Diabetic Neuropathy
Conditions
Interventions
Control Group:Methylcobalamin Tablets 0.5mg, three times a day, orally
Tangbi Group :Tangbi Granules 1 bag, three times a day, prepared by dissolving in water
Methylcobalamin and Tangbi Combination Group:Methylcobalamin Tablets 0.5mg, three times a day, orally plus Tangbi Granules 1 bag, three times a day, prepared by dissolving in water
Sponsors
Jiangsu province hospital of Chinese medicine
Eligibility
Sex/Gender
All
Age
30 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Those who meet the diagnostic criteria for type 2 diabetes combined with Diabetic Peripheral Neuropathy (DPN) in Western medicine and those who fit the syndrome criteria of Yin deficiency and blood stasis in Traditional Chinese Medicine; 2. Those with glycated hemoglobin (HbA1c) =9%; 3. Individuals aged between 30 and 75 years; 4. Those who provide informed consent and volunteer to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Patients who have experienced severe diabetic ketoacidosis or infection within one month or those with severe diabetic foot gangrene; 2. Patients with proliferative diabetic retinopathy who have had photocoagulation events recently; 3. Patients with a history of malignant hypertension myocardial infarction cerebrovascular accidents or other critical conditions within one year and those with congestive heart failure grades I-IV who are currently using anticoagulant or antiplatelet medications; 4. Patients with cancer pregnancy or allergies to drugs in the treatment plan who are not suitable for this treatment regimen; 5. Patients with a history of severe primary heart liver lung kidney blood or severe diseases affecting their survival with blood ALT AST > 2N (N is the upper limit of normal) and Scr > 1.5N. 6. Neuropathies caused by other etiologies such as cervical and lumbar spine diseases (nerve root compression spinal stenosis degenerative changes of the cervical and lumbar spine) cerebral infarction Guillain-Barré syndrome excluding severe arteriovenous vascular diseases (venous thrombosis lymphangitis) and it is also necessary to differentiate the neurotoxic effects of drugs especially chemotherapeutic agents and the damage to nerves caused by metabolic toxins due to renal insufficiency.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Toronto Clinical Score (TCSS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Neurophysiological Testing;Vitalscan;Ankle-Brachial Index;Sudoscan;Gastrointestinal Motility Study;Anxiety and Depression Score; | — |
Countries
China
Contacts
Public ContactLijuan Wang
Jiangsu province hospital of Chinese medicine
Outcome results
None listed